Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines (Q40067422)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines |
scientific article |
Statements
1 reference
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines (English)
1 reference
David R Emlet
1 reference
Kathryn A Brown
1 reference
Deborah L Kociban
1 reference
Agnese A Pollice
1 reference
Charles A Smith
1 reference
Ben Brian L Ong
1 reference
Stanley E Shackney
1 reference
1 October 2007
1 reference
1 reference
Identifiers
1 reference